Bristol Vanlev OCTAVE Data: Angioedema Risk Suggests Second-Line Use
Executive Summary
Bristol-Myers Squibb's Vanlev OCTAVE data suggest that the review of the antihypertensive candidate will focus on a potential second-line indication to the ACE inhibitor enalapril
You may also be interested in...
The Heart Of A Pipeline: Can Novartis Keep The Cardio Portfolio Beating?
The challenge of a generation shift in cardiovascular drugs is not new for Novartis, but the upcoming phase-out of Diovan through 2012 looks more difficult. As the firm prepares to lose Diovan exclusivity, its pipeline reflects an attempt to reprise the time-honored big pharma strategy that carried it through the loss of Lotrel in 2007: mix major efforts to develop novel, first-in-class agents with a push to accelerate its already marketed brands
The Heart Of A Pipeline: Can Novartis Keep The Cardio Portfolio Beating?
The challenge of a generation shift in cardiovascular drugs is not new for Novartis, but the upcoming phase-out of Diovan through 2012 looks more difficult. As the firm prepares to lose Diovan exclusivity, its pipeline reflects an attempt to reprise the time-honored big pharma strategy that carried it through the loss of Lotrel in 2007: mix major efforts to develop novel, first-in-class agents with a push to accelerate its already marketed brands
Bristol Vanlev Settlement Does Not Include Pre-Marketing Results Disclosure
A settlement over allegations that Bristol-Myers Squibb misled investors about its investigational antihypertensive Vanlev does not establish disclosure guidelines for investigational products